Shandong Jincheng Pharmaceutical Group Co., Ltd. announces the progress of transferring drug production technology and MA holder rights. The subsidiary has received full payment and completed the MA holder change. This transfer is expected to impact net profit by approximately 47.17 million RMB, exceeding 10% of the previous year's audited net profit. Investors are advised to be aware of investment risks.
Summary generated by AI · Always verify with source document
Securities Code: 300233 Securities Abbreviation: Jincheng Pharmaceutical Announcement No.: 2026-043
Shandong Jincheng Pharmaceutical Group Co., Ltd.
Announcement on Progress of Transfer of Drug Production Technology and MA Holder Rights
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and there are no false records, misleading statements, or material omissions.
I. Transaction Overview
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.